MRK US58933Y1055

Report

Delayed Nyse - 12/03 04:10:00 pm
73.34	USD		-0.74%

12/03	FDA Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection	BU
12/03	Merck in Supply Agreement With Canada for Antiviral Medicine for Covid-19	DJ
12/03	Merck Canada Announces Supply Agreement of Up to 1 Million Patient Courses of Molnupiravir, an Investigational Oral Antiviral Medicine for the Treatment of COVID-19, with the Government of Canada	AQ

Summary

Quotes 5-day view Delayed Quote.

Delayed Nyse

11/29/2021	11/30/2021	12/01/2021	12/02/2021	12/03/2021	Date
74.89(c)	74.91(c)	74.44(c)	73.89(c)	73.34(c)	Last
34 192 411	30 179 887	21 442 236	15 345 277	13 898 964	Volume
-5.39%	+0.03%	-0.63%	-0.74%	-0.74%	Change

More quotes

Estimated financial data (e) (USD)

Sales 2021	48 572 M - -
Net income 2021	12 378 M - -
Net Debt 2021	20 562 M - -
P/E ratio 2021	15,1x
Yield 2021	3,54%

Sales 2022	56 117 M - -
Net income 2022	16 465 M - -
Net Debt 2022	13 993 M - -
P/E ratio 2022	11,4x
Yield 2022	3,91%

Capitalization	185 B 185 B -
EV / Sales 2021	4,24x
EV / Sales 2022	3,55x
Nbr of Employees	73 500
Free-Float	70,5%

More Financials

Company

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and...

Sector

Pharmaceuticals

Calendar

12/14

Ex-dividend day for

More about the company

Ratings of Merck & Co., Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

B-

More Ratings

All news about MERCK & CO., INC.

12/03	FDA Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pedi..	BU
12/03	Merck in Supply Agreement With Canada for Antiviral Medicine for Covid-19	DJ
12/03	Merck Canada Announces Supply Agreement of Up to 1 Million Patient Courses of Molnupira..	AQ
12/03	Canada Signs Deal for 1 Mln Doses of Pfizer Covid Antiviral and 500K Merck's Covid Pill	MT
12/03	Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl	DJ
12/03	Bristol-Myers Squibb's Supplemental Biologics License Application for Drug Co-Developed..	MT
12/03	KYODO NEWS DIGEST : Dec. 3, 2021 -3-	AQ
12/03	Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL..	AQ
12/03	Nikkei 225 Gains 1% on Merck Covid-19 Drug Application	MT
12/03	U.S. pharma Merck unit seeks Japan's approval of oral COVID drug	AQ
12/03	Merck & Co. Said to Seek Japanese Regulatory Nod for COVID-19 Pill	MT
12/03	Merck Applies for Covid Pill Approval in Japan, Nikkei Reports	DJ
12/03	Tokyo stocks end higher on hopes for COVID-19 oral treatment drug	AQ
12/02	U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for..	AQ
12/02	Federal Court Of Appeal Dismisses Appeal, Upholds Strict Interpretation Of Patent Listi..	AQ

More news

News in other languages on MERCK & CO., INC.

12/03	Merck & Co schließt Liefervereinbarung mit Kanada für Covid-19-Medikament
12/03	MERCK : examen prioritaire de la FDA pour le reblozyl
12/03	Le Nikkei 225 gagne 1 % grâce à la demande d'homologation du médicament Covid-19 de Mer..
12/03	Merck & Co. Merck chercherait à obtenir l'aval des autorités japonaises pour la pilule ..
12/02	CORONA-BLOG/Spahn sichert Deutschland Covid-Medikament Lagevrio von Merck

More news

Analyst Recommendations on MERCK & CO., INC.

11/30	ANALYST RECOMMENDATIONS : Best Buy, Beyond Meat, Booking, Merck, Pfizer...
11/29	SVB Leerink Adjusts Merck & Co.'s Price Target to $102 from $105, Keeps Outperform Rati..	MT
11/29	Morgan Stanley Adjusts Merck & Co.'s Price Target to $82 from $88, Keeps Equalweight Ra..	MT

More recommendations

Provided by Scoopnest.com

Analysis

Merck sees up to $7 billion in sales of COVID-19 drug through end of 2022